Sign up
Pharma Capital

OptiBiotix Health - the commercial momentum continues to build

After a string of deals for its health products, including one earlier this week, the company said it had inked an exclusive agreement in Poland
pic of a man measuring his waist
“This is the first step in taking OptiBiotix's own label GoFigure products to international markets," said sales and marketing director, Christina Wood

The commercial momentum at OptiBiotix Health PLC (LON:OPTI) continues to build.

After a string of deals for its health products, including one earlier this week, the company said it had inked an exclusive agreement in Poland.

The tie-up gives local operator Extensor the rights to distribute OptiBiotix’s GoFigure weight management line across the country.

Sales and marketing director, Christina Wood, said: “This is the first step in taking OptiBiotix's own label GoFigure products to international markets.

“This increases brand recognition and value in addition to creating a demand for SlimBiome, the functional ingredient within GoFigure products.

“This means we are able to derive revenue from both the sale of our own brand GoFigure products and SlimBiome."

Focused on the human microbiome, OptiBiotics has developed a series of products and potential treatments focused on changing the gut flora to tackle obesity, high cholesterol and diabetes.

Ian_55ae0ddd437b7.jpg
Why Invest In OptiBiotix Health PLC? Read More Here

Register here to be notified of future OPTI Company articles
View full OPTI profile View Profile
View All

Related Articles

cancer scan
The company, which owns a piece of software which predicts the effects of drugs on cancers, has recently extended a lucrative agreement with German firm Merck Serono while it has also signed a strategic collaboration with the Medicines Discovery Catapult

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.